Dean Brostowin
Corporate Officer/Principal at Promentis Pharmaceuticals, Inc.
Dean Brostowin active positions
| Companies | Position | Start |
|---|---|---|
Promentis Pharmaceuticals, Inc.
 Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Health Technology |
- Stock Market
- Insiders
- Dean Brostowin
